Glutamatergic neuron markers
Related
At-a-glance- guide to glutamatergic neuron markers
Glutamatergic neurons produce glutamate, which is one of the most common excitatory neurotransmitters in the central nervous system (CNS).
vGluT1
A glutamate transporter that transports cytoplasmic glutamate into vesicles.
Zebrafish retina sections stained with anti-vGluT1 (green) (ab77822).
vGluT2
A glutamate transporter that transports cytoplasmic glutamate into vesicles.
Mouse brain tissue sections stained with anti-vGluT2 (ab79157).
NMDAR1
An essential subunit of all NMDA receptors.
Rat cortex stained with anti-NMDAR1 (ab17345).
NMDAR1 modulators
| Product | Activity |
| (+)-MK 801 maleate (Dizocilpine) (ab120027) | Non-competitive NMDAR1 antagonist. ion channel. |
NMDAR1 antagonist. | |
| Eliprodil (ab145971) | Non-competitive specific inhibitor of NMDAR1 and/or NMDAR2B subunits. |
NMDAR2B
Another NMDA receptor subunit. This subunit forms the glutamate binding site on the NMDA receptors.
Mouse cerebral cortex sections stained with anti-NMDAR2B (ab65783).
Browse all NMDAR2B antibodies
NMDAR2B modulators
| Product | Activity |
| NGHVYEKLSSIE (Interfering peptide) (ab120380) | Peptide (agonist) that competes with clathrin adaptor protein (AP-2) binding to NR2B. |
| Eliprodil (ab145971) | Non-competitive specific inhibitor of NMDAR1 and/or NMDAR2B subunits. |
| Gentiopicrin (ab143623) | Downregulates GluN2B-containing NMDA receptors in the NAc. |
| Ro 25-6981 maleate salt (ab120290) | Potent, highly selective, activity-dependent inhibitor of NMDA receptors that contain the NR2B subunit. |
| Ifenprodil hemitartrate (ab120111) | Non-competitive NMDAR2B antagonist acting at the polyamine site. |
Glutaminase
An enzyme catalyzing the deamination of glutamine into glutamate.
Human cerebral cortex tissue labeled with anti-glutaminase (ab156876).
Glutamine synthetase
An enzyme catalyzing the ATP-dependent amidation of glutamate to form glutamine. It is primarily expressed in astrocytes but expression levels rise in neurons in neurodenegerative diseases. When staining for glutamine synthetase, we recommend parallel use of NeuN.
Zebrafish retina sections stained with anti-glutamine synthetase (purple) (ab93439).
References
- Baude, A., Strube, C., Tell, F. & Kessler, J.-P. Glutamatergic neurotransmission in the nucleus tractus solitarii: structural and functional characteristics. J. Chem. Neuroanat. 38, 145–53 (2009).
- Bhatt, J. M., Prakash, A., Suryavanshi, P. S. & Dravid, S. M. Effect of ifenprodil on GluN1/GluN2B N-methyl-D-aspartate receptor gating. Mol. Pharmacol. 83, 9–21 (2013).
- Fernandes, S. P., Dringen, R., Lawen, A. & Robinson, S. R. Neurones express glutamine synthetase when deprived of glutamine or interaction with astrocytes. J. Neurochem. 114, 1527–36 (2010).
- Fischer, G. et al. Ro 25-6981, a highly potent and selective blocker of N-methyl-D-aspartate receptors containing the NR2B subunit. Characterization in vitro. J. Pharmacol. Exp. Ther. 283, 1285–92 (1997).
- Kotlinska, J. & Liljequist, S. Oral administration of glycine and polyamine receptor antagonists blocks ethanol withdrawal seizures. Psychopharmacology (Berl). 127, 238–244 (1996).
- Kovacic, P. & Somanathan, R. Clinical physiology and mechanism of dizocilpine (MK-801): electron transfer, radicals, redox metabolites and bioactivity. Oxid. Med. Cell. Longev. 3, 13–22
- Liu, S.-B. et al. Gentiopicroside attenuates morphine rewarding effect through downregulation of GluN2B receptors in nucleus accumbens. CNS Neurosci. Ther. 18, 652–8 (2012).
- North, W. G., Gao, G., Jensen, A., Memoli, V. A. & Du, J. NMDA receptors are expressed by small-cell lung cancer and are potential targets for effective treatment. Clin. Pharmacol. 2, 31–40 (2010).
- Prybylowski, K. et al. The synaptic localization of NR2B-containing NMDA receptors is controlled by interactions with PDZ proteins and AP-2. Neuron 47, 845–57 (2005).
- Wang, T. & Miller, K. E. Characterization of glutamatergic neurons in the rat atrial intrinsic cardiac ganglia that project to the cardiac ventricular wall. Neuroscience 329, 134–150 (2016).
- Wyss-Coray, T. et al. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer’s mice. Proc. Natl. Acad. Sci. U. S. A. 99, 10837–10842 (2002).